SAN DIEGO, July 10, 2018 /PRNewswire/ -- Arena
Pharmaceuticals, Inc. (Nasdaq: ARNA), a biopharmaceutical company
focused on delivering novel, transformational medicines across
multiple therapeutic areas, today announced the appointment of
Kieran T. Gallahue as a
non-executive director. Mr. Gallahue is a highly accomplished
executive with over 25 years of leadership experience in
publicly-traded life sciences companies.
"We are thrilled to have Kieran join our board of directors,"
said Tina Nova, Chairman of the
Board of Directors of Arena. "His extraordinary leadership
experience in the life sciences industry will be invaluable as we
position the Company for long-term, sustainable growth. We look
forward to leveraging Kieran's extensive expertise as we plan the
path forward for our rapidly advancing, multi-product, Phase 3
ready pipeline."
Mr. Gallahue served as Chairman and Chief Executive Officer of
CareFusion Corporation, a medical products company, from 2011 until
its acquisition by Becton, Dickinson and Company in 2015 for
$12.3 billion. He previously served
as President, CEO and a director of ResMed, a medical device firm
serving the sleep disordered breathing and respiratory markets, and
also held a variety of senior-level positions at Nanogen, Inc.,
Instrumentation Laboratory, Procter & Gamble Co., and General
Electric Co. Mr. Gallahue is currently a member of the boards of
directors of medical device companies, Edwards Lifesciences
Corporation and Intersect ENT. He previously served on the board of
directors of Volcano Corporation, a developer of products for
interventional cardiology and image guided therapy, from 2007 until
its acquisition by Royal Philips in
2015. Mr. Gallahue also served on the Executive Committee of the
Advanced Medical Technology Association, a trade association
representing 80% of medical technology firms in the United States. He holds a bachelor's
degree in Economics from Rutgers
University and an MBA from Harvard
Business School.
About Arena Pharmaceuticals
Arena Pharmaceuticals is
focused on delivering novel, transformational medicines with
optimized pharmacology and pharmacokinetics to patients globally.
Arena's proprietary pipeline includes multiple potentially first-
or best-in-class programs with broad clinical utility. The most
advanced investigational clinical programs are ralinepag (APD811),
which will be commencing a Phase 3 program for pulmonary arterial
hypertension (PAH), and etrasimod (APD334), which will be
commencing a Phase 3 program for ulcerative colitis (UC) and a
program in Crohn's Disease (CD), and which has potential utility
for a broad range of immune and inflammatory conditions. Arena is
also evaluating olorinab (APD371) in Phase 2 for the treatment of
visceral pain associated with Crohn's disease, as well as other
drug candidates in earlier research and development stages.
In addition, Arena has several collaborations including Everest
Medicines Limited (ralinepag and etrasimod in Greater China and select Asian countries),
Axovant Sciences GmbH (nelotanserin - Phase 2), Boehringer
Ingelheim International GmbH (undisclosed target - preclinical),
Outpost Medicine, LLC (undisclosed target – preclinical), and Eisai
Co., Ltd. and Eisai Inc. (BELVIQ® - marketed
product).
Forward-Looking Statements
Certain statements in this
press release are forward-looking statements that involve a number
of risks and uncertainties. These forward-looking statements may be
accompanied by words such as "focused on," "will," "position the
Company for," "look forward to," "plan," "path forward,"
"potentially," "potential," or words of similar meaning, or by the
fact that they do not relate strictly to historical or current
facts. Such forward-looking statements include, without limitation,
statements about Arena's potential for long-term, sustainable
growth, programs (including their first- or best-in-class
potential), focus and collaborations. For such statements, Arena
claims the protection of the Private Securities Litigation Reform
Act of 1995. Actual events or results may differ materially from
Arena's expectations. Factors that could cause actual results to
differ materially from the forward-looking statements include that
the timing and outcome of research, development and regulatory
review is uncertain; clinical programs may not proceed at the time
or in the manner expected or at all; results of clinical trials and
other studies are subject to different interpretations and may not
be predictive of future results; and other risks related to
developing and commercializing drugs. Additional factors that could
cause actual results to differ materially from those stated or
implied by Arena's forward-looking statements are disclosed in
Arena's filings with the Securities and Exchange Commission (SEC),
including but not limited to our Quarterly Report on Form 10-Q for
the quarter ended March 31, 2018,
which was filed with the SEC on May 9,
2018. These forward-looking statements represent Arena's
judgment as of the time of this release. Arena disclaims any intent
or obligation to update these forward-looking statements, other
than as may be required under applicable law.
Corporate Contact:
Kevin R. Lind
Arena Pharmaceuticals, Inc.
Executive Vice President and
Chief Financial Officer
klind@arenapharm.com
858.210.3636
Media Contact:
Matt Middleman, M.D.
LifeSci Public Relations
matt.middleman@lifescipublicrelations.com
646.627.8384
View original content with
multimedia:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-appoints-life-sciences-industry-veteran-kieran-t-gallahue-to-board-of-directors-300678085.html
SOURCE Arena Pharmaceuticals, Inc.